PPHMVERY LONG, this is a tough one to naysay. Since I've been here about as long as you have, and have lost credibility because of my gullibility, I am going to sit back with my dwindling holdings and simply hold on while the new generation comes along and carries the ball over the goal line. As mentioned, from a clinical point of view, this diagnostic business is an absolute blockbuster with potential that is even greater than naked Bavi or Bavi with a skirt on. I would not consider selling at this point, and I have been sorely tempted in the past 24 months. I think we have a winner at last. And this is only the beginning for the antiphospholipid platform. I have said for years that it is the spin-offs that count in the end, and we are only glimpsing the beginning.
News 
Market Data 
Discover 
AI
